MEMRI and Kidney Disease

Launched by UNIVERSITY OF EDINBURGH · Nov 18, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a new imaging technique called manganese-enhanced magnetic resonance imaging (MEMRI) to see if it can help identify patients with kidney disease who are at risk of developing heart problems. Acute kidney injury (AKI) is a common condition that can lead to serious complications, including chronic kidney disease (CKD) and cardiovascular disease. By using MEMRI, researchers hope to better understand how the kidneys and heart handle calcium, which could help in predicting health outcomes for patients suffering from kidney issues.

To participate in the trial, you must be over 18 years old and able to give written consent. There are several groups of people who can be included, such as those recently diagnosed with AKI, individuals with chronic kidney disease, or patients who have had kidney transplants. Participants will undergo certain tests and imaging to assess their kidney and heart function. It's important to know that some people may not be eligible due to specific health conditions or if they are currently pregnant. Overall, this study aims to find new ways to monitor and improve care for people with kidney disease and its related heart risks.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• All subjects to be entered must:
• • Be able to provide written informed consent after having received oral and written information about the study.
• • \>18 years of age Availability to complete study visits If female, be non-pregnant as evidenced by a negative pregnancy test or be post-menopausal or surgically sterile.
• Additionally, cohort specific inclusion criteria are as follows:
• • Cohort 1; Acute kidney injury-
• A diagnosis of AKI will be made based on the following criteria (based on the definition used in the Kidney Precision Medicine Project www.kpmp.org):
• • Previous (within 3 years) eGFR \>45 ml/min/1.73m2 OR no history of kidney disease if no blood results available AND Elevated creatinine \>1.5x previous result OR \>150 μmol/L if no previous value AND Increasing creatinine within 48 hours OR requirement for dialysis.
• • Cohort 2; Chronic kidney disease- Stable CKD for at least 6 months (monitored by eGFR), matched to AKI cohort at follow up based on renal function.
• • Cohort 3: Matched controls- Matched to AKI cohort participants at baseline for age, sex, cardiovascular disease risk and cardiovascular medication.
• • Cohort 4; Vasculitis- A new diagnosis of vasculitis or an existing diagnosis with relapsing disease, and kidney involvement.
• • Cohort 5; Kidney transplantation- Has kidney failure and has received a kidney transplant in the preceding 1 month.
• • Cohort 6: Kidney transplant rejection- Biopsy proven episode of transplant rejection.
• Exclusion Criteria:
• The following criteria apply to all patients:
• • 1. Unable to give informed consent.
• • 2. Have any contraindications to standard MRI safety criteria, including implanted devices.
• • 3. Subjects under the age of 18 years old.
• • 4. Pregnancy/positive pregnancy test.
• • 5. Current breastfeeding.
• • 6. Have a diagnosis of kidney disease due to polycystic kidney disease.
• • 7. Patients in critical care or on surgical wards will be excluded.
• • 8. Patients taking calcium channel antagonists or digoxin.
• Additionally, cohort specific exclusion criteria are as follow:
• • Cohort 1- Excluded if they have a diagnosis of diabetes. Cohort 2- Excluded if receiving dialysis or those with a functional kidney transplant, multi-system disorders (e.g., systemic vasculitis), or any patients receiving immunosuppression.